ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pimicotinib

Also written as “pimicotinib capsules”, “ABSK021” and “Pimicotinib”.

Its studies are mostly in Giant Cell Tumor of Tendon Sheath · Synovitis, Pigmented Villonodular · Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Drug pagePimicotinib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 13, 202314 company-led studies, 6 open or runningNext primary completion: Aug 22, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Cayman135 open or runningphase 3since Mar 13, 2023Nov 27, 2019Dec 31, 2031phase 1 · NCT04192344
Merck KGaA, Darmstadt, Germanyits history only11 open or runningphase 2since Mar 23, 2026Mar 23, 2026Aug 22, 2028phase 2 · NCT07499362

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbisko Cayman only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2019First study: phase 1 study in NeoplasmsFirst studyNCT04192344 · 276 planned · United States, China
  2. Mar 7, 2022Phase 1 study in NeoplasmsNCT05280483 · 16 enrolled · China
  3. Mar 13, 2023Phase 3 study in Giant Cell Tumor of Tendon SheathNCT05804045 · 94 enrolled · United States, Canada, China and more
  4. Aug 6, 2023Named pimicotinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ABSK021
  5. Oct 20, 2023Phase 2 study in Advanced Pancreatic CancerNCT06111274 · 82 planned · China
  6. Nov 20, 2023Phase 1 study in Healthy SubjectsNCT06186583 · 6 enrolled · China
  7. Nov 28, 2023Phase 2 study in cGvHDNCT06186804 · 64 planned · China
  8. Feb 29, 2024Phase 1 study in Healthy SubjectsNCT06322706 · 36 enrolled · China
  9. Aug 18, 2024Phase 1 study in PharmacokineticsNCT06562946 · 24 enrolled · China
  10. Nov 14, 2024Phase 1 study in PharmacokineticsNCT06694948 · 26 enrolled · China
  11. Jan 9, 2025Phase 1 study in Healthy SubjectsNCT06779253 · 39 enrolled · China
  12. Mar 13, 2025Phase 1 study in Healthy SubjectsNCT06884072 · 16 enrolled · China
  13. Aug 3, 2025Phase 1 study in PharmacokineticsNCT07126249 · 38 enrolled · China
  14. Sep 30, 2025Phase 1 study in Pharmacokinetics in Healthy VolunteersNCT07210996 · 20 enrolled · China
  15. Nov 9, 2026Primary completion moved from 2026-12-31 to 2031-12-31Date moved laterphase 1 · +60 months · NCT04192344

Ahead

  1. Dec 31, 2031Primary completion: phase 1 study in NeoplasmsNCT04192344

TargetBeta

CSF1R →read by rule
“An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
axatilimabruleIncytephase 312
vimseltinibruleOno Pharmaceuticalphase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

All 13 Abbisko Cayman leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07210996Pharmacokinetics in Healthy Volunteers · China1CompletedOct 6, 202520
NCT07126249Pharmacokinetics · China1CompletedJun 6, 202538
NCT06884072Healthy Subjects · China1Active, not recruitingJul 1, 202516
NCT06779253Healthy Subjects · China1CompletedApr 4, 202539
NCT06694948Pharmacokinetics · China1CompletedJan 3, 202526
NCT06562946Pharmacokinetics · China1CompletedDec 30, 202424
NCT06322706Healthy Subjects · China1CompletedNov 1, 202436
NCT06186804cGvHD · China2By invitationOct 30, 202664
NCT06186583Healthy Subjects · China1CompletedMay 30, 20246
NCT06111274Advanced Pancreatic Cancer · China2RecruitingDec 30, 202582
NCT05804045Giant Cell Tumor of Tendon Sheath · United States, Canada, China and more3Active, not recruitingSep 23, 202494
NCT05280483Neoplasms · China1CompletedAug 31, 202216
NCT04192344Neoplasms · United States, China1RecruitingDec 31, 2031276

How it is read

Names in the registry

  • “pimicotinib capsules”, 4 entries
  • “ABSK021”, 3 entries
  • “Pimicotinib”, 2 entries
  • “Pimicotinib(ABSK021)”, 1 entry
  • “Pimicotinib capsule”, 1 entry

Codes read as this program: ABSK021.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.